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Marc Schnitzler, Jens Hasskarl, Matthias Egger, Hartmut Bertz, Ju¨rgen FinkeDevelopment of severe steroid-resistant acute graft-versus-host disease (GVHD) after allogeneic hemato-
poietic cell transplantation (HCT) is associated with poor outcome. The humanized monoclonal antibody
alemtuzumab was shown to be effective in GVHD prophylaxis in conditioning regimens before allogeneic
HCT. We evaluated the efficacy and safety of alemtuzumab in 20 patients with histologically confirmed ste-
roid refractory grade III and IV intestinal GVHD after related and unrelated HCT. Overall response rate was
70%, with complete response in 35%. Despite the severe grade of GVHD in our patients, the median survival
of 280 days and 1-year overall survival (OS) of 50% were superior or comparable to those associated with
other treatment options. Cytomegalovirus (CMV) reactivation, bacterial infection, and invasive aspergillosis
were frequent complications; however, infection was not a significant predictor for survival. These data sug-
gest that treatment with alemtuzumab has favorable activity in severe intestinal GVHD after allogeneic HCT,
but emphasize the importance of careful monitoring and anti-infectious supportive care.
Biol Blood Marrow Transplant 15: 910-918 (2009)  2009 American Society for Blood and Marrow TransplantationKEY WORDS: Allogeneic hematopoietic cell transplantation, Alemtuzumab, Graft-versus-host disease,
BudenosideINTRODUCTION
Acute graft-versus-host disease (aGVHD) is a fre-
quent and important complication after allogeneic he-
matopoietic cell transplantation (HCT). Most patients
respond to corticosteroid treatment, but patients with
severe forms of GVHD often fail to improve [1,2].
Topical steroids, such as budesonide, might reduce
the need for systemic immunosuppressants and posi-
tively influence the course of intestinal GVHD [1,3].
Despite intensive immunosuppressive treatment op-
tions with monoclonal antibodies (mAbs), antithymo-
cyte globulin (ATG), and combinations of
immunosuppressive agents, a standard therapy for cor-
ticosteroid-refractory GVHD has yet to be defined
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/09/158-0001$36.00/0
6/j.bbmt.2009.04.002Because GVHD is a T lymphocyte-dependent
process, targeting of donor-derived T lymphocytes
for therapy of GVHD is a feasible approach. Daclizu-
mab, a mAb against the alpha chain of the interleukin
(IL)-2 receptor (CD25) has been used to treat steroid-
resistant aGVHD [4,5]. Response rates were promis-
ing (54%–90%). Event-free survival (EFS) was
54.6% at 4 years in one report [4]; in another report,
median survival in patients with grade III or IV
aGVHD was 2 months [5]. Basiliximab also has been
used to treat steroid-refractory aGVHD, with re-
ported response rates of 71% to 83% and a 45%
1-year survival in a phase II trial [6,7]. Denileukin is
a recombinant fusion protein of human IL-2 and the
active domains of diphtheria toxin. Response rates of
92% and a median survival of 7.2 months were re-
ported in a phase I trial in patients with predominantly
grade III or IV aGVHD (63%) [8]. Tumor necrosis
factor alpha (TNFa) is another therapeutic target for
treating GVHD. The TNFa antibody infliximab and
the soluble dimeric TNFa receptor decoy etanercept
have been used successfully to treat GVHD [9-11]; un-
fortunately, however, these results are not comparable
because of a small case series, the inclusion of patients
with chronic GVHD (cGVHD), or the drug’s use as
first-line therapy. Other treatment options include
ATG [12], mesenchymal stem cells [13-15], pentosta-
tin [16], and mycophenolate mofetil (MMF) [17,18].
Although response rates were promising for grade
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Biol Blood Marrow Transplant 15:910-918, 2009 911Alemtuzumab in Severe Intestinal GVHDI-II GVHD (51% to 83%), patients with grade III and
IV GVHD still have a very limited prognosis, demon-
strating the need for more effective therapies. The
humanized monoclonal antibody (mAb) alemtuzumab
targets CD52, which is expressed on B and T lympho-
cytes and antigen-presenting cells (APCs). Although
alemtuzumab has been used within various GVHD
prophylaxis protocols [19,20], its use in treating severe
aGVHD has not been studied systematically. Only
a few case reports and only a single case series have
evaluated its efficacy in this setting [21-23].PATIENTS AND METHODS
Patients
A retrospective computerized search in our elec-
tronic patient documentation system helped identify
20 consecutive transplant recipients who had received
alemtuzumab for treatment of severe steroid-resistant
aGVHD between May 2005 and March 2007, at our
institution. All patients had received peripheral blood
stem cell (PBSC) transplants from HLA-matched re-
lated donors (MRDs; n5 9) or HLA-matched unre-
lated donors (MUDs; n5 11). Records (electronic
and paper) of these patients were reviewed. Although
data had been collected prospectively, this patient se-
ries did not fulfill the criteria for a formal study.
Diagnosis of GVHD
The diagnosis and grading of intestinal aGVHD
were based on clinical criteria before day 1100 [24]
and were confirmed both endoscopically [25] and his-
tologically [26,27] and graded according to the endo-
scopic and histological grading system proposed by
Cruz-Correa et al. [28]. All patients included in this
analysis had been followed for at least 1 year or until
death. Infections possibly mimicking GVHD were
ruled out histologically and microbiologically. A
routine panel of enteritic pathogens was performed
on the first presentation of diarrhea and during fol-
low-up. Routine virology studies via enzyme-linked
immunosorbent assay (ELISA) included rotavirus, ad-
enovirus, cytomegalovirus (CMV), and norovirus on
clinical suspicion. Stool cultures were screened for mi-
crosporidia, Cryptosporidium species, Campylobacter,
Salmonella species, Yersinia, and Clostridium difficile
(culture plus ELISA).
Definition of Steroid-Resistant aGVHD
Consistent with previously reported criteria [29-31],
all patients who exhibited no clinical improvement to
steroid treatment (2 mg/kg/day of prednisone for
a minimum of 4 days) or had nonimproving grade
III-IV aGVHD after at least 7 days of prednisone ther-
apy (2 mg/kg/day) were defined as steroid-refractory.
912 Biol Blood Marrow Transplant 15:910-918, 2009M. Schnitzler et al.Nonimproving aGVHD was defined as a lack of im-
provement or deterioration in clinical signs and symp-
toms in any involved organ. All patients had received
cyclosporine A (CsA), which was continued through-
out the clinical course.
Response to Alemtuzumab
Patients initially received 10 mg of alemtuzumab
intravenously, and treatment was repeated weekly until
symptoms resolved or complications appeared. Steroid
doses were rapidly tapered within 5 days of the first
alemtuzumab injection.
Staging and grading of aGVHD was recorded
weekly after the first day of alemtuzumab treatment.
Response was assessed according to previously pub-
lished criteria [30], based on clinical criteria and histo-
logical control biopsy specimens. Complete response
was defined as absence of diarrhea without the use of
antimotility agents and/or normal endoscopy findings
and absence of GVHD in other organs. In patients
with persistent clinical GVHD, endoscopic reevalua-
tion was performed within 1 month. Partial response
required reduction in at least 1 stage in control histol-
ogy or striking clinical improvement with significant
reduction of stool volume (resolution of diarrhea, or
decrease in the 3-day average stool frequency with
clearing of cramps and bleeding, if present). Persistent
GVHDwas diagnosed when clinical symptoms did not
improve and control biopsy specimens failed to show
improvement of GVHD. Because clinically stable pa-
tients were treated rapidly in our outpatient clinic,
a definite time to response was not available for these
patients and could only be estimated. Stool frequency,
stool consistency, and patient-estimated stool volume
were reported by outpatients. cGVHD was graded ac-
cording to the National Institutes of Health (NIH)
consensus criteria [32]. Written informed consent for
use of alemtuzumab and data acquisition for research
purposes in concordance with our hospital’s Ethics
Committee was obtained from all patients in accor-
dance with the Declaration of Helsinki. Overall sur-
vival (OS) was analyzed using the Kaplan-Meier
method, and predictors of survival were evaluated by
log-rank (Mantel-Cox) and Gehan-Breslow-Wilcoxon
tests using GraphPad Prism version 5.00 for MacOSX
(GraphPad Software, San Diego, CA).RESULTS
All patients who received a PBSC transplant had
a hematologic malignancy as the underlying disease
(Tables 2 and 3). Nine patients (45%) received
grafts from HLA-identical siblings (ie, MRDs), and
11 patients (55%) received grafts from HLA-
MUDs. Patients initially presented with aGVHD
(n5 11), late-onset aGVHD (n5 6), or donor lym-phocyte infusion (DLI)-induced (n5 3) intestinal
GVHD. Median time between transplantation and
onset of intestinal GVHD was 47 days (range, 30 to
71 days) in aGVHD, 137 days (range, 115 to 167
days) in late-onset aGVHD, and 231 days (range,
162 to 275 days) in DLI-induced GVHD. Seven pa-
tients (35%) had grade III GVHD, and 13 patients
(65%) had grade IV aGVHD. All patients had abdom-
inal symptoms (eg, large-volume diarrhea, abdominal
pain, cramps). Patient characteristics are summarized
in Tables 2 and 3. Median time between the start of
prednisone therapy (2 mg/kg) and initial administra-
tion of alemtuzumab was 7 days (range, 4 to 30
days). Patients received amedian of 2 doses of alemtu-
zumab (20 mg; range, 1 to 5 [10 to 50 mg]). All pa-
tients received additional treatment with oral
budesonide (3 3 mg) (3). Budesonide was initiated
after clinical diagnosis of intestinal GVHD (ie, onset
of diarrhea). Our rationale for using budesonide to
treat intestinal aGVHD comes from our experience
that budesonide can improve GVHD symptoms and
decrease the need for systemic immunosuppression
[3]. All patients were fasting and received parenteral
nutrition at the time of diagnosis of steroid-resistant
GVHD. Oral food intake was reinitiated stepwise af-
ter clinical improvement was noted. Analogous to
treatment of inflammatory bowel disease [33], 13 of
20 patients received MMF after histopathologic diag-
nosis of aGVHD (Table 2) [25]. Ten patients were ini-
tially treated with intravenous MMF and later
switched to oral formulation. Oral prednisone was ta-
pered within 5 days after the first dose of alemtuzu-
mab.Response and Survival
The overall response rate to alemtuzumab was
70% (6 patients with partial response and 8 with com-
plete response [CR]). Six patients (30%) did not re-
spond to alemtuzumab. Patients who were evaluable
for all quantitative parameters (n5 10; 50%) had ame-
dian time to clinical response of 12 days from the first
alemtuzumab dose (range, 6 to 24 days). Among the
patients with partial response or CR, 64% developed
limited cGVHD. Neither response to alemtuzumab
nor survival was dose-dependent. Eight of the 20 pa-
tients (40%) survived, with a median follow up of
834 days (range, 199 to 1176 days), 7 in complete
remission and 1 with cGVHD requiring continued im-
munosuppression with everolimus. Six patients (30%)
had relapsed or progressed before the start of alemtu-
zumab treatment. After the initiation of alemtuzumab
treatment, 6 patients (30%) experienced relapse or
progression of underlying malignant disease. Another
3 patients developed relapse of hematologic malig-
nancy after first dose of alemtuzumab. Thus, 8 of 9 pa-
tients who were not in complete remission of
Table 2. GVHD Scores and Outcomes of 20 Patients with Steroid-Refractory GVHD Treated with Alemtuzumab
Patient
Skin-
Liver-Gut Overall
GVHD
Onset, Day aGVHDAI*
Nonrelapse
Mortality on
Day 200
Histological
Grade Histological Findings Endoscopy Findings
Remission
Status
1 0-0-3 III 44 74 0.30 Grade III Extensive mucosal defects.
Severe apoptosis in crypts
with complete destruction
Colon ascendens, transversum,
and descendens with
confluent hemorrhagic
lesions, partially fibrin-
covered
CR
2 0-1-3 III 131 90 0.40 Grade III Mucosa with erosive
inflammation and destruction
of crypts and intraepithelial
apoptosis
Erythema and edema of mucosa
with severe defects and
partial abrasion
CR
3 0-0-3 III 115 70 0.28 Grade III GVHD grade II-III Edematous mucosa with
aphthous lesions, partially
ulcerating lesions
CR
4 0-0-3 III 42 74 0.30 Grade III Extensive mucosal defects with
loss of crypts and grouped
epithelial apoptosis
Mucosa erythematous and
multiple aphthous lesions
CR
5 0-3-3 III 30 100 0.60 Grade III Multiple intraepithelial
apoptosis and superficial loss
of epithelium
Mucosal defects and ulcerations Relapse
6 0-0-4 IV 48 74 0.30 Grade IV Completely destroyed mucosa
instead of granulation tissue
Erythematous mucosa with
extensive ulcerations and
defects
CR
7 0-0-4 IV 73 54 0.25 Grade IV Mucosal fragments with
multiple intraepithelial
apoptosis, with destruction
of crypts and virtually
complete loss of mucosa and
concomitant inflammation
Erythematous mucosa with
extensive ulcerations and
defects
CR
8 0-0-4 IV 32 90 0.40 Grade IV Loss of superficial and deep
(crypts) epithelium. Within
remaining mucosa, multiple
apoptosis.
Mucosa erythematous, partially
aphthous lesions
Relapse
9 3-3-4 IV 151 80 0.38 Grade IV Mucosa without dysplasia with
almost complete loss of
epithelium and multiple
apoptosis
Erythematous mucosa with
extensive ulcerations and
defects
CR
10 0-2-4 IV 135 90 0.40 Grade IV Mucosa with severe
inflammation and destruction
of mucosa with granulation
tissue Multiple apoptosis
Fibrin-covered mucosal defects
with reddened walls
CR
(Continued )
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Table 2. (Continued )
Patient
Skin-
Liver-Gut Overall
GVHD
Onset, Day aGVHDAI*
Nonrelapse
Mortality on
Day 200
Histological
Grade Histological Findings Endoscopy Findings
Remission
Status
11 0-1-4 IV 46 90 0.40 Grade IV Confluent ulcerating mucosa Erythematous mucosa with
extensive ulcerations and
defects
Relapse
12 3-0-4 IV 71 74 0.30 Grade IV Completely ulcerated mucosa Erythematous mucosa with
extensive ulcerations and
defects
CR
13 2-0-4 IV 40 90 0.40 Grade IV Almost complete loss of
epithelium and crypts
Edematous mucosa with
aphthous lesions, partially
ulcerating lesions
CR
14 0-0-4 IV 167 74 0.30 Grade IV Extensive erosive changes, only
few regenerating crypts with
apoptosis
Erythematous mucosa with
extensive ulcerations and
defects
CR
15 3-0-3 III 55 74 0.30 Grade III Marked destruction of normal
mucosal architecture,
increased intraepithelial
apoptosis with focal defects
of epithelium
Edematous mucosa with
aphthous lesions, partially
ulcerating lesions
PD
16 0-0-4 IV 57 74 0.30 Grade IV Extensive loss of epithelial
structures with apoptotic
bodies
Erythematous mucosa with
extensive ulcerations and
defects
PD
17 3-3-3 IV 139 100 0.60 Grade III Multiple apoptosis, destruction
of crypts, and large mucosal
defects with signs of
regeneration
Erythematous mucosa with
extensive ulcerations and
defects
CR
18 2-0-3 III 162 90 0.40 Grade III Multiple erosive lesions Edematous mucosa with
multiple aphthous and
ulcerating lesions
Relapse
19 0-0-4 IV 275 74 0.30 Grade IV Multiple erosive and ulcerating
mucosal lesions
Erythematous mucosa with
extensive ulcerations and
defects
CR
20 3-4-4 IV 231 100 0.60 Grade IV Almost complete loss of
epithelium and crypts
Erythematous mucosa with
extensive ulcerations and
defects
Relapse
PD indicates progressive disease; CR, complete response; aGVHDAI, acute graft versus host disease Activity Index.
*aGVHDAI to predict day 200 nonrelapse mortality [34].
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Table 3. Disease, Patient, and Treatment Characteristics of All 20 Patients with Steroid-Refractory GVHD Treated with Alemtuzumab
Patient
Age,
Years Sex Diagnosis Donor GVHD Prophylaxis
Remission
Status
at Onset
Onset,
Day
Days of Steroid
Therapy before
First Alemtuzumab
Dose
Alemtuzumab
Dose MMF
GVHD
Response
Survival, Days
from First
Alemtuzumab
Dose cGVHD
Remission
Status
Cessation of
Immunosuppression,
Days from First
Alemtuzumab Dose
1 56 F AML MUD CyA/MTX CR 44 4 20 mg No PR +1176 + CR 245*
2 50 M MDS MUD CyA/MMF/ATG40 CR 131 6 20 mg Yes NR 24 - CR -
3 68 M SAML MUD CyA/MMF/ATG40 CR 115 7 10 mg Yes CR 653 + CR 223*
4 64 M NHL MUD CyA/MMF/ATG40 CR 42 30 50 mg Yes NR 126 - CR -
5 50 F AML MUD CyA/MTX/ATG60 CR 30 10 20 mg Yes NR 46 - Relapse -
6 36 M SAML MRD CyA CR 48 7 40 mg Yes PR +810 + CR 679
7 47 M MM MUD CyA/MMF/ATG30 CR 73 10 20 mg Yes CR +851 - CR 122
8 58 M SAML MUD CyA/MMF/ATG40 CR 32 5 50 mg No PR 106 + Relapse -
9 46 M CML MUD CyA/alemtuzumab10 CR 151 6 10 mg No CR +796 + CR 694
10 22 F CALL MUD CyA/MTX CR 135 4 30 mg Yes CR +1043 + CR 995*
11 57 M AML MRD CyA/Campath10 CR 46 7 50 mg No NR 149 - Relapse -
12 43 M AML MRD CyA/MTX CR 71 4 20 mg Yes PR +199 - CR -
13 51 M MDS MRD CyA/MTX CR 40 7 30 mg Yes PR 145 + CR -
14 54 M MDS MUD CyA/MMF/ATG40 CR 167 15 40 mg No CR +966 + CR 376
15 60 M MM MUD CyA/MMF/ATG30 PD 55 5 20 mg Yes CR 555 + PD 189
16 43 F MM MRD CyA/Campath10 PD 57 13 10 mg Yes CR 90 - PD -
17 50 M CML MRD CyA/MTX Relapse 139 15 20 mg Yes NR 70 - CR -
18 56 M SAML MRD CyA/Campath20 Relapse DLI 162 24 30 mg No CR 280 - Relapse -
19 41 M TMDS MRD CyA/Campath20 Relapse DLI 275 4 40 mg Yes PR +816 - CR -
20 63 F AML MRD CyA/Campath20 Relapse DLI 231 11 10 mg No NR 5 - Relapse -
51 72 7 20 mg (2 doses) 240
AML indicates acute myelogenous leukemia; sAML, secondary AML; MM, multiple myeloma; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; tMDS, therapy-related MDS; NHL, non-Hodgkin
lymphoma; ALL, acute lymphoblastic leukemia; CyA, cyclosporine A; MTX, methotrexate; PD, progressive disease.
Bottom numbers: Median, + alive; *5 mg prednisone for cGVHD.
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Figure 1. Survival and nonrelapse mortality of patients with severe ste-
roid-refractory GVHD after first treatment with alemtuzumab. (A) Sur-
vival function depending on response to alemtuzumab. The dotted line
represents survival of patients responding to alemtuzumab; the solid
line, survival of patients not responding to alemtuzumab; the black
line, survival of all patients. Censored subjects are indicated. (B) Frac-
tional risk of death in patients with or without relapse of underlying dis-
ease. The dashed line represents relapse mortality after treatment with
alemtuzumab; the dotted line, nonrelapse mortality after treatment with
alemtuzumab; the solid line, risk of death for all patients. Censored sub-
jects are marked.
916 Biol Blood Marrow Transplant 15:910-918, 2009M. Schnitzler et al.malignant disease before or after the onset of aGVHD
died. In contrast, 8 of 11 patients with complete remis-
sion before and after DLI survived. Patients who did
not respond to alemtuzumab therapy had a poor prog-
nosis (median survival, 48 days; range, 5 to 149 days; P
\ .0001) (Figure 1A). The probability of nonrelapse
mortality was estimated using the average aGVHD
Activity Index (aGVHDAI) on day 1 after HCT [34]
(Table 2), although whether this index has been tested
and validated for steroid-resistant aGVHD is not
clear. Three patients, 1 of whom had received addi-
tional DLI treatment after recovering from a first
GVHD episode, died from progression of GVHD.
Four patients died from infectious complications, 4
died from relapsing or progressive malignant disease,
and 1 died at home of an unknown cause. Negative
predictors for survival were relapse or progression of
underlying malignancy (P5 .0069) and lack of re-
sponse to alemtuzumab (P\ .0001) (Figure 1A and
B). No significant association between survival and
type of underlying disease, grade of GVHD, infection,
transplantation from anMUD, or additional treatment
with MMF was noted.Infectious Complications
Seven patients (35%) suffered from Aspergillus
pneumonia, of whom 2 died from progressive invasive
aspergillosis. Aspergillus antigen was measured in se-
rum samples once a week using the galactomannan
test. Bacterial pneumonia was found in 8 patients,
and additional sepsis occurred in 2 patients. CMV re-
activation was monitored twice weekly and found to be
a frequent complication. Two patients developed
histologically confirmed CMV colitis. Gancicloivir
therapy was initiated in all patients with CMV reacti-
vation when copies exceeded 1000/mL, and CMV in-
fection resolved in all patients. Epstein-Barr virus
(EBV) reactivation was monitored at least monthly.
Three patients (15%) developed EBV reactivation,
with. 50,000/mL copies, at a median time of 33 days
after the first alemtuzumab dose (range, 23 to 52
days). After treatment with rituximab (375 mg/m2),
EBV-DNA levels normalized. No patient developed
posttransplantation lymphoproliferative disease.DISCUSSION
Here, we report the use of alemtuzumab to treat
severe steroid-resistant intestinal aGVHD after
HSCT from related and unrelated donors. Despite
various attempts to treat severe steroid-resistant
aGVHD, with reported response rates of 44% to
75%, the prognosis remains grave. Our response rate
of 70% is comparable to results reported from other
trials using various agents (Table 1). Our median OS
of 9.2 months in all patients treated compares favor-
ably with OS in patients with steroid-refractory
aGVHD treated with other agents. Nevertheless,
only those patients who responded to alemtuzumab
exhibited a clear clinical benefit. Although bacterial in-
fectious complications were frequent, they were not
life-threatening. Fungal pneumonia was a major con-
cern despite early therapy. Toprevent fungal infection,
standard prophylaxis with fluconazole was provided.
Aspergillus-specific therapy with voriconazole or lipo-
somal amphotericin B was initiated in patients experi-
encing persistent fever after empirical antibiotic
escalation with a broad-spectrum antibiotic and a gly-
copeptide, in those exhibiting a positive galacto-
mannan test, or in those with clinically suspected
aspergillosis. Meanwhile, low-dose computed tomog-
raphy scans were performed in those patients consid-
ered at high risk for pulmonary aspergillosis. As has
been reported for alemtuzumab therapy in GVHD
prophylaxis protocols, CMV reactivation was a com-
mon complication. We routinely monitored CMV
copy number at least once weekly, and initiated antivi-
ral therapy when the CMV copy number reached 1000
copies/mL. EBV copy number was monitored weekly.
Rituximab therapy was initiated based on a positive
Biol Blood Marrow Transplant 15:910-918, 2009 917Alemtuzumab in Severe Intestinal GVHDpolymerase chain reaction assay for EBV (. 20,000
copies/mL or increasing copy numbers) and clinical
suspicion for EBV reactivation.
In summary, we have shown that alemtuzumab is
active and safe for treating even severe aGVHD
when closely monitored. Despite the severe grade of
GVHD in our patients, OS was superior or compara-
ble to that from other treatment options. Our results
warrant a larger randomized trial to test alemtuzumab
for early therapy of aGVHD. Possibly lower doses (ie,
3 to 5 mg alemtuzumab s.c.) should be used, to better
control for infection and relapse. The effect of MMF
and budesonide therapy, after diagnosis of GVHD
and before the initiation of alemtuzumab therapy, can-
not be conclusively determined; thus, our approach is
a combined one that remains to be validated in a larger
prospective study.ACKNOWLEDGMENTS
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